Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD
Status:
Terminated
Trial end date:
2017-11-30
Target enrollment:
Participant gender:
Summary
Open-label extension study to evaluate the safety of long-term twice-monthly administration
of somavaratan in adults with Growth Hormone Deficiency (GHD).